PD
NVCT icon

Point72 (DIFC)’s Nuvectis Pharma NVCT Stock Holding History

Point72 (DIFC)’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-49
Closed -$265 – 1946
2024
Q4 		$265 Buy
+49
New +$307 ﹤0.01% 1448
2024
Q3 		– Sell
-1,249
Closed -$7.91K – 1701
2024
Q2 		$7.91K Buy
+1,249
New +$8.49K ﹤0.01% 1331

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AWM
Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

Point72 (DIFC)'s NVCT Position: Q1 2025 in Review

Point72 (DIFC) sold out of Nuvectis Pharma (NVCT) in Q1 2025, closing a stake of 49 shares — an estimated $265 sold.

Point72 (DIFC) first reported a position in NVCT in Q2 2024 and held it in 2 quarters. The position peaked at $7.91K in Q2 2024. 33 funds tracked by Wall St. Rank hold NVCT as of Q1 2025.

  • Point72 (DIFC) reported no remaining Nuvectis Pharma position as of Q1 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 49 Nuvectis Pharma shares in Q1 2025, an estimated $265.
  • Point72 (DIFC) first reported a position in Nuvectis Pharma in Q2 2024 and held it in 2 quarters.
  • Point72 (DIFC)'s Nuvectis Pharma position peaked at $7.91K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.